AEON Biopharma Closes $25 Million in Convertible Debt

Represented AEON Biopharma, Inc. in a subordinated convertible debt financing from an undisclosed investor.  The long-term commitment of the investor will provide sufficient capital to enable the expansion of AEON Biopharma’s clinical development programs into 2021.

AEON Biopharma, Inc. (formerly known as ALPHAEON Corporation) is a private biotechnology company focused on the development of therapeutic indications for its proprietary botulinum toxin complex.  On September 3, 2020, AEON announced that the FDA had accepted AEON Biopharma’s Investigational New Drug application to treat cervical dystonia, a neurological condition characterized by involuntary muscle contractions and significant pain.